# A Study of the Safety and PK of PCS6422 (Eniluracil) with Capecitabine in Patients with Advanced, Refractory GI Tract Tumors

> **NCT04861987** · PHASE1 · COMPLETED · sponsor: **Processa Pharmaceuticals** · enrollment: 23 (actual)

## Conditions studied

- Advanced Cancer
- Refractory Cancer
- Tumor Gastric

## Interventions

- **DRUG:** PCS6422 and capecitabine

## Key facts

- **NCT ID:** NCT04861987
- **Lead sponsor:** Processa Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-18
- **Primary completion:** 2024-06-12
- **Final completion:** 2024-09-09
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2024-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04861987

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04861987, "A Study of the Safety and PK of PCS6422 (Eniluracil) with Capecitabine in Patients with Advanced, Refractory GI Tract Tumors". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04861987. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*